APO Research
Talk to an analyst

APO RESEARCH · REPORT

Tumor Necrosis Factor Inhibitors Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Tumor Necrosis Factor Inhibitors Drug Industry Growth and Trends Forecast to 2032

22 December 2025129 pages

Choose your research edition.

Industry ResearchTumor Necrosis Factor Inhibitors Drug Industry Research Report 2026147 pages · $2,950 USDIndustry Growth & TrendsGlobal Tumor Necrosis Factor Inhibitors Drug Industry Growth and Trends Forecast to 2032129 pages · $3,450 USDMarket StructureGlobal Tumor Necrosis Factor Inhibitors Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Tumor Necrosis Factor Inhibitors Drug Market Outlook and Growth Opportunities 2026218 pages · $4,250 USDMarket Analysis & ForecastGlobal Tumor Necrosis Factor Inhibitors Drug Market Analysis and Forecast 2026-2032210 pages · $4,950 USD

Market perspective

The global Tumor Necrosis Factor Inhibitors Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Tumor Necrosis Factor Inhibitors Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Tumor Necrosis Factor Inhibitors Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Tumor Necrosis Factor Inhibitors Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Tumor Necrosis Factor Inhibitors Drug include Sandoz, Novartis, GlaxoSmithKline, Zydus Cadila, UCB, Tsumura, Toyama Chemical, Simcere Pharmaceutical and Shanghai Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Tumor Necrosis Factor Inhibitors Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Tumor Necrosis Factor Inhibitors Drug market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Tumor Necrosis Factor Inhibitors Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Tumor Necrosis Factor Inhibitors Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Tumor Necrosis Factor Inhibitors Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Tumor Necrosis Factor Inhibitors Drug Market by Company

Sandoz

Novartis

GlaxoSmithKline

Zydus Cadila

UCB

Tsumura

Toyama Chemical

Simcere Pharmaceutical

Shanghai Pharmaceuticals

Shanghai CP Guojian Pharmaceutical

Sanofi-Aventis

Samsung Bioepis

Reliance Life Sciences

PROBIOMED

Momenta Pharmaceuticals

MedImmune

LG Life Sciences

LEO Pharma

Janssen Biotech

Intas Pharmaceuticals

HanAll Biopharma

EPIRUS Biopharmaceuticals

Dexa Medica

Delenex Therapeutics

Celltrion

Celgene Corporation

CASI Pharmaceuticals

Bionovis

AryoGen Biopharma

Apogenix

Tumor Necrosis Factor Inhibitors Drug Segment by Type

Enbrel (Etanercept)

Simponi (Golimumab)

Cimzia (Certolizumab Pegol)

Remicade (Infliximab)

Otezla (Apremilast)

Humira ( Adalimumab)

Tumor Necrosis Factor Inhibitors Drug Segment by Application

Clinic

Hospital

Others

Tumor Necrosis Factor Inhibitors Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tumor Necrosis Factor Inhibitors Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Tumor Necrosis Factor Inhibitors Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tumor Necrosis Factor Inhibitors Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Tumor Necrosis Factor Inhibitors Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Tumor Necrosis Factor Inhibitors Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Enbrel (Etanercept) Table 2. Major Company of Simponi (Golimumab) Table 3. Major Company of Cimzia (Certolizumab Pegol) Table 4. Major Company of Remicade (Infliximab) Table 5. Major Company of Otezla (Apremilast) Table 6. Major Company of Humira ( Adalimumab) Table 7. Global Tumor Necrosis Factor Inhibitors Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 8. Global Tumor Necrosis Factor Inhibitors Drug Sales by Type (2021-2026) & (k units) Table 9. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Volume by Type (2021-2026) Table 10. Global Tumor Necrosis Factor Inhibitors Drug Sales by Type (2021-2026) & (US$ Million) Table 11. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Value by Type (2021-2026) Table 12. Global Tumor Necrosis Factor Inhibitors Drug Price by Type (2021-2026) & (US$/unit) Table 13. Global Tumor Necrosis Factor Inhibitors Drug Sales by Type (2027-2032) & (k units) Table 14. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Volume by Type (2027-2032) Table 15. Global Tumor Necrosis Factor Inhibitors Drug Sales by Type (2027-2032) & (US$ Million) Table 16. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Value by Type (2027-2032) Table 17. Global Tumor Necrosis Factor Inhibitors Drug Price by Type (2027-2032) & (US$/unit) Table 18. North America Tumor Necrosis Factor Inhibitors Drug Sales by Type (2021-2026) & (k units) Table 19. North America Tumor Necrosis Factor Inhibitors Drug Sales by Type (2021-2026) & (US$ Million) Table 20. Europe Tumor Necrosis Factor Inhibitors Drug Sales by Type (2021-2026) & (k units) Table 21. Europe Tumor Necrosis Factor Inhibitors Drug Sales by Type (2021-2026) & (US$ Million) Table 22. Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales by Type (2021-2026) & (k units) Table 23. Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales by Type (2021-2026) & (US$ Million) Table 24. Latin America Tumor Necrosis Factor Inhibitors Drug Sales by Type (2021-2026) & (k units) Table 25. Latin America Tumor Necrosis Factor Inhibitors Drug Sales by Type (2021-2026) & (US$ Million) Table 26. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales by Type (2021-2026) & (k units) Table 27. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales by Type (2021-2026) & (US$ Million) Table 28. Tumor Necrosis Factor Inhibitors Drug Industry Trends Table 29. Tumor Necrosis Factor Inhibitors Drug Industry Drivers Table 30. Tumor Necrosis Factor Inhibitors Drug Industry Opportunities and Challenges Table 31. Tumor Necrosis Factor Inhibitors Drug Industry Restraints Table 32. Global Tumor Necrosis Factor Inhibitors Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 33. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Company (2021-2026) Table 34. Global Tumor Necrosis Factor Inhibitors Drug Sales by Company (2021-2026) & (k units) Table 35. Global Tumor Necrosis Factor Inhibitors Drug Sales Share by Company (2021-2026) Table 36. Global Tumor Necrosis Factor Inhibitors Drug Market Price by Company (2021-2026) & (US$/unit) Table 37. Global Tumor Necrosis Factor Inhibitors Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 38. Global Tumor Necrosis Factor Inhibitors Drug Major Company Production Sites and Headquarters Table 39. Global Tumor Necrosis Factor Inhibitors Drug Company, Product Type & Application Table 40. Global Tumor Necrosis Factor Inhibitors Drug Company Establishment Date Table 41. Global Company Market Concentration Ratio (CR5 and HHI) Table 42. Global Tumor Necrosis Factor Inhibitors Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 43. Global Tumor Necrosis Factor Inhibitors Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 44. Global Tumor Necrosis Factor Inhibitors Drug Sales by Region (2021-2026) & (k units) Table 45. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Volume by Region (2021-2026) Table 46. Global Tumor Necrosis Factor Inhibitors Drug Sales by Region (2021-2026) & (US$ Million) Table 47. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Value by Region (2021-2026) Table 48. Global Tumor Necrosis Factor Inhibitors Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 49. Global Tumor Necrosis Factor Inhibitors Drug Sales by Region (2027-2032) & (k units) Table 50. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Volume by Region (2027-2032) Table 51. Global Tumor Necrosis Factor Inhibitors Drug Sales by Region (2027-2032) & (US$ Million) Table 52. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Value by Region (2027-2032) Table 53. Global Tumor Necrosis Factor Inhibitors Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 54. Global Tumor Necrosis Factor Inhibitors Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 55. Global Tumor Necrosis Factor Inhibitors Drug Sales by Application (2021-2026) & (k units) Table 56. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Volume by Application (2021-2026) Table 57. Global Tumor Necrosis Factor Inhibitors Drug Sales by Application (2021-2026) & (US$ Million) Table 58. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Value by Application (2021-2026) Table 59. Global Tumor Necrosis Factor Inhibitors Drug Price by Application (2021-2026) & (US$/unit) Table 60. Global Tumor Necrosis Factor Inhibitors Drug Sales by Application (2027-2032) & (k units) Table 61. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Volume by Application (2027-2032) Table 62. Global Tumor Necrosis Factor Inhibitors Drug Sales by Application (2027-2032) & (US$ Million) Table 63. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Value by Application (2027-2032) Table 64. Global Tumor Necrosis Factor Inhibitors Drug Price by Application (2027-2032) & (US$/unit) Table 65. North America Tumor Necrosis Factor Inhibitors Drug Sales by Application (2021-2026) & (k units) Table 66. North America Tumor Necrosis Factor Inhibitors Drug Sales by Application (2021-2026) & (US$ Million) Table 67. Europe Tumor Necrosis Factor Inhibitors Drug Sales by Application (2021-2026) & (k units) Table 68. Europe Tumor Necrosis Factor Inhibitors Drug Sales by Application (2021-2026) & (US$ Million) Table 69. Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales by Application (2021-2026) & (k units) Table 70. Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales by Application (2021-2026) & (US$ Million) Table 71. Latin America Tumor Necrosis Factor Inhibitors Drug Sales by Application (2021-2026) & (k units) Table 72. Latin America Tumor Necrosis Factor Inhibitors Drug Sales by Application (2021-2026) & (US$ Million) Table 73. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales by Application (2021-2026) & (k units) Table 74. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales by Application (2021-2026) & (US$ Million) Table 75. Sandoz Company Information Table 76. Sandoz Business Overview Table 77. Sandoz Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 78. Sandoz Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 79. Sandoz Recent Development Table 80. Novartis Company Information Table 81. Novartis Business Overview Table 82. Novartis Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 83. Novartis Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 84. Novartis Recent Development Table 85. GlaxoSmithKline Company Information Table 86. GlaxoSmithKline Business Overview Table 87. GlaxoSmithKline Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 88. GlaxoSmithKline Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 89. GlaxoSmithKline Recent Development Table 90. Zydus Cadila Company Information Table 91. Zydus Cadila Business Overview Table 92. Zydus Cadila Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. Zydus Cadila Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 94. Zydus Cadila Recent Development Table 95. UCB Company Information Table 96. UCB Business Overview Table 97. UCB Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 98. UCB Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 99. UCB Recent Development Table 100. Tsumura Company Information Table 101. Tsumura Business Overview Table 102. Tsumura Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 103. Tsumura Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 104. Tsumura Recent Development Table 105. Toyama Chemical Company Information Table 106. Toyama Chemical Business Overview Table 107. Toyama Chemical Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 108. Toyama Chemical Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 109. Toyama Chemical Recent Development Table 110. Simcere Pharmaceutical Company Information Table 111. Simcere Pharmaceutical Business Overview Table 112. Simcere Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 113. Simcere Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 114. Simcere Pharmaceutical Recent Development Table 115. Shanghai Pharmaceuticals Company Information Table 116. Shanghai Pharmaceuticals Business Overview Table 117. Shanghai Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 118. Shanghai Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 119. Shanghai Pharmaceuticals Recent Development Table 120. Shanghai CP Guojian Pharmaceutical Company Information Table 121. Shanghai CP Guojian Pharmaceutical Business Overview Table 122. Shanghai CP Guojian Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 123. Shanghai CP Guojian Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 124. Shanghai CP Guojian Pharmaceutical Recent Development Table 125. Sanofi-Aventis Company Information Table 126. Sanofi-Aventis Business Overview Table 127. Sanofi-Aventis Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 128. Sanofi-Aventis Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 129. Sanofi-Aventis Recent Development Table 130. Samsung Bioepis Company Information Table 131. Samsung Bioepis Business Overview Table 132. Samsung Bioepis Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 133. Samsung Bioepis Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 134. Samsung Bioepis Recent Development Table 135. Reliance Life Sciences Company Information Table 136. Reliance Life Sciences Business Overview Table 137. Reliance Life Sciences Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 138. Reliance Life Sciences Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 139. Reliance Life Sciences Recent Development Table 140. PROBIOMED Company Information Table 141. PROBIOMED Business Overview Table 142. PROBIOMED Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 143. PROBIOMED Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 144. PROBIOMED Recent Development Table 145. Momenta Pharmaceuticals Company Information Table 146. Momenta Pharmaceuticals Business Overview Table 147. Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 148. Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 149. Momenta Pharmaceuticals Recent Development Table 150. MedImmune Company Information Table 151. MedImmune Business Overview Table 152. MedImmune Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 153. MedImmune Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 154. MedImmune Recent Development Table 155. LG Life Sciences Company Information Table 156. LG Life Sciences Business Overview Table 157. LG Life Sciences Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 158. LG Life Sciences Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 159. LG Life Sciences Recent Development Table 160. LEO Pharma Company Information Table 161. LEO Pharma Business Overview Table 162. LEO Pharma Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 163. LEO Pharma Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 164. LEO Pharma Recent Development Table 165. Janssen Biotech Company Information Table 166. Janssen Biotech Business Overview Table 167. Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 168. Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 169. Janssen Biotech Recent Development Table 170. Intas Pharmaceuticals Company Information Table 171. Intas Pharmaceuticals Business Overview Table 172. Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 173. Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 174. Intas Pharmaceuticals Recent Development Table 175. HanAll Biopharma Company Information Table 176. HanAll Biopharma Business Overview Table 177. HanAll Biopharma Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 178. HanAll Biopharma Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 179. HanAll Biopharma Recent Development Table 180. EPIRUS Biopharmaceuticals Company Information Table 181. EPIRUS Biopharmaceuticals Business Overview Table 182. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 183. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 184. EPIRUS Biopharmaceuticals Recent Development Table 185. Dexa Medica Company Information Table 186. Dexa Medica Business Overview Table 187. Dexa Medica Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 188. Dexa Medica Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 189. Dexa Medica Recent Development Table 190. Delenex Therapeutics Company Information Table 191. Delenex Therapeutics Business Overview Table 192. Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 193. Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 194. Delenex Therapeutics Recent Development Table 195. Celltrion Company Information Table 196. Celltrion Business Overview Table 197. Celltrion Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 198. Celltrion Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 199. Celltrion Recent Development Table 200. Celgene Corporation Company Information Table 201. Celgene Corporation Business Overview Table 202. Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 203. Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 204. Celgene Corporation Recent Development Table 205. CASI Pharmaceuticals Company Information Table 206. CASI Pharmaceuticals Business Overview Table 207. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 208. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 209. CASI Pharmaceuticals Recent Development Table 210. Bionovis Company Information Table 211. Bionovis Business Overview Table 212. Bionovis Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 213. Bionovis Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 214. Bionovis Recent Development Table 215. AryoGen Biopharma Company Information Table 216. AryoGen Biopharma Business Overview Table 217. AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 218. AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 219. AryoGen Biopharma Recent Development Table 220. Apogenix Company Information Table 221. Apogenix Business Overview Table 222. Apogenix Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 223. Apogenix Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 224. Apogenix Recent Development Table 225. North America Tumor Necrosis Factor Inhibitors Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 226. North America Tumor Necrosis Factor Inhibitors Drug Sales by Country (2021-2026) & (k units) Table 227. North America Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Country (2021-2026) Table 228. North America Tumor Necrosis Factor Inhibitors Drug Sales Forecast by Country (2027-2032) & (k units) Table 229. North America Tumor Necrosis Factor Inhibitors Drug Sales Market Share Forecast by Country (2027-2032) Table 230. North America Tumor Necrosis Factor Inhibitors Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 231. North America Tumor Necrosis Factor Inhibitors Drug Market Size by Country (2021-2026) & (US$ Million) Table 232. North America Tumor Necrosis Factor Inhibitors Drug Market Share by Country (2021-2026) Table 233. North America Tumor Necrosis Factor Inhibitors Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 234. North America Tumor Necrosis Factor Inhibitors Drug Market Share Forecast by Country (2027-2032) Table 235. Europe Tumor Necrosis Factor Inhibitors Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 236. Europe Tumor Necrosis Factor Inhibitors Drug Sales by Country (2021-2026) & (k units) Table 237. Europe Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Country (2021-2026) Table 238. Europe Tumor Necrosis Factor Inhibitors Drug Sales Forecast by Country (2027-2032) & (k units) Table 239. Europe Tumor Necrosis Factor Inhibitors Drug Sales Market Share Forecast by Country (2027-2032) Table 240. Europe Tumor Necrosis Factor Inhibitors Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 241. Europe Tumor Necrosis Factor Inhibitors Drug Market Size by Country (2021-2026) & (US$ Million) Table 242. Europe Tumor Necrosis Factor Inhibitors Drug Market Share by Country (2021-2026) Table 243. Europe Tumor Necrosis Factor Inhibitors Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 244. Europe Tumor Necrosis Factor Inhibitors Drug Market Share Forecast by Country (2027-2032) Table 245. Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 246. Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales by Country (2021-2026) & (k units) Table 247. Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Country (2021-2026) Table 248. Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales Forecast by Country (2027-2032) & (k units) Table 249. Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales Market Share Forecast by Country (2027-2032) Table 250. Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 251. Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Market Size by Country (2021-2026) & (US$ Million) Table 252. Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Market Share by Country (2021-2026) Table 253. Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 254. Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Market Share Forecast by Country (2027-2032) Table 255. Latin America Tumor Necrosis Factor Inhibitors Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 256. Latin America Tumor Necrosis Factor Inhibitors Drug Sales by Country (2021-2026) & (k units) Table 257. Latin America Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Country (2021-2026) Table 258. Latin America Tumor Necrosis Factor Inhibitors Drug Sales Forecast by Country (2027-2032) & (k units) Table 259. Latin America Tumor Necrosis Factor Inhibitors Drug Sales Market Share Forecast by Country (2027-2032) Table 260. Latin America Tumor Necrosis Factor Inhibitors Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 261. Latin America Tumor Necrosis Factor Inhibitors Drug Market Size by Country (2021-2026) & (US$ Million) Table 262. Latin America Tumor Necrosis Factor Inhibitors Drug Market Share by Country (2021-2026) Table 263. Latin America Tumor Necrosis Factor Inhibitors Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 264. Latin America Tumor Necrosis Factor Inhibitors Drug Market Share Forecast by Country (2027-2032) Table 265. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 266. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales by Country (2021-2026) & (k units) Table 267. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Country (2021-2026) Table 268. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales Forecast by Country (2027-2032) & (k units) Table 269. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales Market Share Forecast by Country (2027-2032) Table 270. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 271. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Market Size by Country (2021-2026) & (US$ Million) Table 272. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Market Share by Country (2021-2026) Table 273. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 274. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Market Share Forecast by Country (2027-2032) Table 275. Key Raw Materials Table 276. Raw Materials Key Suppliers Table 277. Tumor Necrosis Factor Inhibitors Drug Distributors List Table 278. Tumor Necrosis Factor Inhibitors Drug Customers List Table 279. Research Programs/Design for This Report Table 280. Authors List of This Report Table 281. Secondary Sources Table 282. Primary Sources List of Figures Figure 1. Tumor Necrosis Factor Inhibitors Drug Image Figure 2. Global Tumor Necrosis Factor Inhibitors Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Tumor Necrosis Factor Inhibitors Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Tumor Necrosis Factor Inhibitors Drug Sales (2021-2032) & (k units) Figure 5. Enbrel (Etanercept) Image Figure 6. Global Enbrel (Etanercept) Sales YoY Growth (2021-2032) & (k units) Figure 7. Simponi (Golimumab) Image Figure 8. Global Simponi (Golimumab) Sales YoY Growth (2021-2032) & (k units) Figure 9. Cimzia (Certolizumab Pegol) Image Figure 10. Global Cimzia (Certolizumab Pegol) Sales YoY Growth (2021-2032) & (k units) Figure 11. Remicade (Infliximab) Image Figure 12. Global Remicade (Infliximab) Sales YoY Growth (2021-2032) & (k units) Figure 13. Otezla (Apremilast) Image Figure 14. Global Otezla (Apremilast) Sales YoY Growth (2021-2032) & (k units) Figure 15. Humira ( Adalimumab) Image Figure 16. Global Humira ( Adalimumab) Sales YoY Growth (2021-2032) & (k units) Figure 17. Global Tumor Necrosis Factor Inhibitors Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 18. Global Tumor Necrosis Factor Inhibitors Drug Market Share by Type 2025 VS 2032 Figure 19. North America Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Volume by Type in 2025 Figure 20. North America Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Value by Type in 2025 Figure 21. Europe Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Volume by Type in 2025 Figure 22. Europe Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Value by Type in 2025 Figure 23. Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Volume by Type in 2025 Figure 24. Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Value by Type in 2025 Figure 25. Latin America Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Volume by Type in 2025 Figure 26. Latin America Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Value by Type in 2025 Figure 27. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Volume by Type in 2025 Figure 28. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Value by Type in 2025 Figure 29. Global Top 5 and 10 Tumor Necrosis Factor Inhibitors Drug Players Market Share by Revenue in 2025 Figure 30. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 31. Clinic Image Figure 32. Global Clinic Sales YoY Growth (2021-2032) & (k units) Figure 33. Hospital Image Figure 34. Global Hospital Sales YoY Growth (2021-2032) & (k units) Figure 35. Others Image Figure 36. Global Others Sales YoY Growth (2021-2032) & (k units) Figure 37. Global Tumor Necrosis Factor Inhibitors Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 38. Global Tumor Necrosis Factor Inhibitors Drug Market Share by Application 2025 VS 2032 Figure 39. North America Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Volume by Application in 2025 Figure 40. North America Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Value by Application in 2025 Figure 41. Europe Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Volume by Application in 2025 Figure 42. Europe Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Value by Application in 2025 Figure 43. Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Volume by Application in 2025 Figure 44. Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Value by Application in 2025 Figure 45. Latin America Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Volume by Application in 2025 Figure 46. Latin America Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Value by Application in 2025 Figure 47. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Volume by Application in 2025 Figure 48. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales Market Share in Value by Application in 2025 Figure 49. North America Tumor Necrosis Factor Inhibitors Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 50. North America Tumor Necrosis Factor Inhibitors Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. North America Tumor Necrosis Factor Inhibitors Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. North America Tumor Necrosis Factor Inhibitors Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Tumor Necrosis Factor Inhibitors Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 54. Europe Tumor Necrosis Factor Inhibitors Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Europe Tumor Necrosis Factor Inhibitors Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Europe Tumor Necrosis Factor Inhibitors Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 58. Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Tumor Necrosis Factor Inhibitors Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 62. Latin America Tumor Necrosis Factor Inhibitors Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Latin America Tumor Necrosis Factor Inhibitors Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Latin America Tumor Necrosis Factor Inhibitors Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 66. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 67. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 68. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 69. Tumor Necrosis Factor Inhibitors Drug Value Ch

Scope & coverage.

Types
  • Enbrel (Etanercept)
  • Simponi (Golimumab)
  • Cimzia (Certolizumab Pegol)
  • Remicade (Infliximab)
  • Otezla (Apremilast)
  • Humira ( Adalimumab)
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Sandoz
  • Novartis
  • GlaxoSmithKline
  • Zydus Cadila
  • UCB
  • Tsumura
  • Toyama Chemical
  • Simcere Pharmaceutical
  • Shanghai Pharmaceuticals
  • Shanghai CP Guojian Pharmaceutical
  • Sanofi-Aventis
  • Samsung Bioepis
  • Reliance Life Sciences
  • PROBIOMED
  • Momenta Pharmaceuticals
  • MedImmune
  • LG Life Sciences
  • LEO Pharma
  • Janssen Biotech
  • Intas Pharmaceuticals
  • HanAll Biopharma
  • EPIRUS Biopharmaceuticals
  • Dexa Medica
  • Delenex Therapeutics
  • Celltrion
  • Celgene Corporation
  • CASI Pharmaceuticals
  • Bionovis
  • AryoGen Biopharma
  • Apogenix

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Tumor Necrosis Factor Inhibitors Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Tumor Necrosis Factor Inhibitors Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Tumor Necrosis Factor Inhibitors Drug Market by Type
  6. 1.3.1 Enbrel (Etanercept)
  7. 1.3.2 Simponi (Golimumab)
  8. 1.3.3 Cimzia (Certolizumab Pegol)
  9. 1.3.4 Remicade (Infliximab)
  10. 1.3.5 Otezla (Apremilast)
  11. 1.3.6 Humira ( Adalimumab)
  12. 1.4 Global Tumor Necrosis Factor Inhibitors Drug Market Size by Type
  13. 1.4.1 Global Tumor Necrosis Factor Inhibitors Drug Market Size Overview by Type (2021-2032)
  14. 1.4.2 Global Tumor Necrosis Factor Inhibitors Drug Historic Market Size Review by Type (2021-2026)
  15. 1.4.3 Global Tumor Necrosis Factor Inhibitors Drug Forecasted Market Size by Type (2027-2032)
  16. 1.5 Key Regions Market Size by Type
  17. 1.5.1 North America Tumor Necrosis Factor Inhibitors Drug Sales Breakdown by Type (2021-2026)
  18. 1.5.2 Europe Tumor Necrosis Factor Inhibitors Drug Sales Breakdown by Type (2021-2026)
  19. 1.5.3 Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales Breakdown by Type (2021-2026)
  20. 1.5.4 South America Tumor Necrosis Factor Inhibitors Drug Sales Breakdown by Type (2021-2026)
  21. 1.5.5 Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Tumor Necrosis Factor Inhibitors Drug Industry Trends
  2. 2.2 Tumor Necrosis Factor Inhibitors Drug Industry Drivers
  3. 2.3 Tumor Necrosis Factor Inhibitors Drug Industry Opportunities and Challenges
  4. 2.4 Tumor Necrosis Factor Inhibitors Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Tumor Necrosis Factor Inhibitors Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by Tumor Necrosis Factor Inhibitors Drug Sales (2021-2026)
  3. 3.3 Global Top Players by Tumor Necrosis Factor Inhibitors Drug Price (2021-2026)
  4. 3.4 Global Tumor Necrosis Factor Inhibitors Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Tumor Necrosis Factor Inhibitors Drug Major Company Production Sites & Headquarters
  6. 3.6 Global Tumor Necrosis Factor Inhibitors Drug Company, Product Type & Application
  7. 3.7 Global Tumor Necrosis Factor Inhibitors Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Tumor Necrosis Factor Inhibitors Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Tumor Necrosis Factor Inhibitors Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Tumor Necrosis Factor Inhibitors Drug Tier 1, Tier 2, and Tier 3
4 Tumor Necrosis Factor Inhibitors Drug Regional Status and Outlook
  1. 4.1 Global Tumor Necrosis Factor Inhibitors Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Tumor Necrosis Factor Inhibitors Drug Historic Market Size by Region
  3. 4.2.1 Global Tumor Necrosis Factor Inhibitors Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Tumor Necrosis Factor Inhibitors Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Tumor Necrosis Factor Inhibitors Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Tumor Necrosis Factor Inhibitors Drug Forecasted Market Size by Region
  7. 4.3.1 Global Tumor Necrosis Factor Inhibitors Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Tumor Necrosis Factor Inhibitors Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Tumor Necrosis Factor Inhibitors Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Tumor Necrosis Factor Inhibitors Drug by Application
  1. 5.1 Tumor Necrosis Factor Inhibitors Drug Market by Application
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Tumor Necrosis Factor Inhibitors Drug Market Size by Application
  6. 5.2.1 Global Tumor Necrosis Factor Inhibitors Drug Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Tumor Necrosis Factor Inhibitors Drug Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Tumor Necrosis Factor Inhibitors Drug Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Tumor Necrosis Factor Inhibitors Drug Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Tumor Necrosis Factor Inhibitors Drug Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Tumor Necrosis Factor Inhibitors Drug Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Sandoz
  2. 6.1.1 Sandoz Company Information
  3. 6.1.2 Sandoz Business Overview
  4. 6.1.3 Sandoz Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Sandoz Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  6. 6.1.5 Sandoz Recent Developments
  7. 6.2 Novartis
  8. 6.2.1 Novartis Company Information
  9. 6.2.2 Novartis Business Overview
  10. 6.2.3 Novartis Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Novartis Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  12. 6.2.5 Novartis Recent Developments
  13. 6.3 GlaxoSmithKline
  14. 6.3.1 GlaxoSmithKline Company Information
  15. 6.3.2 GlaxoSmithKline Business Overview
  16. 6.3.3 GlaxoSmithKline Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 GlaxoSmithKline Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  18. 6.3.5 GlaxoSmithKline Recent Developments
  19. 6.4 Zydus Cadila
  20. 6.4.1 Zydus Cadila Company Information
  21. 6.4.2 Zydus Cadila Business Overview
  22. 6.4.3 Zydus Cadila Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Zydus Cadila Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  24. 6.4.5 Zydus Cadila Recent Developments
  25. 6.5 UCB
  26. 6.5.1 UCB Company Information
  27. 6.5.2 UCB Business Overview
  28. 6.5.3 UCB Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 UCB Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  30. 6.5.5 UCB Recent Developments
  31. 6.6 Tsumura
  32. 6.6.1 Tsumura Company Information
  33. 6.6.2 Tsumura Business Overview
  34. 6.6.3 Tsumura Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Tsumura Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  36. 6.6.5 Tsumura Recent Developments
  37. 6.7 Toyama Chemical
  38. 6.7.1 Toyama Chemical Company Information
  39. 6.7.2 Toyama Chemical Business Overview
  40. 6.7.3 Toyama Chemical Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Toyama Chemical Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  42. 6.7.5 Toyama Chemical Recent Developments
  43. 6.8 Simcere Pharmaceutical
  44. 6.8.1 Simcere Pharmaceutical Company Information
  45. 6.8.2 Simcere Pharmaceutical Business Overview
  46. 6.8.3 Simcere Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Simcere Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  48. 6.8.5 Simcere Pharmaceutical Recent Developments
  49. 6.9 Shanghai Pharmaceuticals
  50. 6.9.1 Shanghai Pharmaceuticals Company Information
  51. 6.9.2 Shanghai Pharmaceuticals Business Overview
  52. 6.9.3 Shanghai Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Shanghai Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  54. 6.9.5 Shanghai Pharmaceuticals Recent Developments
  55. 6.10 Shanghai CP Guojian Pharmaceutical
  56. 6.10.1 Shanghai CP Guojian Pharmaceutical Company Information
  57. 6.10.2 Shanghai CP Guojian Pharmaceutical Business Overview
  58. 6.10.3 Shanghai CP Guojian Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Shanghai CP Guojian Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  60. 6.10.5 Shanghai CP Guojian Pharmaceutical Recent Developments
  61. 6.11 Sanofi-Aventis
  62. 6.11.1 Sanofi-Aventis Company Information
  63. 6.11.2 Sanofi-Aventis Business Overview
  64. 6.11.3 Sanofi-Aventis Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Sanofi-Aventis Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  66. 6.11.5 Sanofi-Aventis Recent Developments
  67. 6.12 Samsung Bioepis
  68. 6.12.1 Samsung Bioepis Company Information
  69. 6.12.2 Samsung Bioepis Business Overview
  70. 6.12.3 Samsung Bioepis Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Samsung Bioepis Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  72. 6.12.5 Samsung Bioepis Recent Developments
  73. 6.13 Reliance Life Sciences
  74. 6.13.1 Reliance Life Sciences Company Information
  75. 6.13.2 Reliance Life Sciences Business Overview
  76. 6.13.3 Reliance Life Sciences Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Reliance Life Sciences Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  78. 6.13.5 Reliance Life Sciences Recent Developments
  79. 6.14 PROBIOMED
  80. 6.14.1 PROBIOMED Company Information
  81. 6.14.2 PROBIOMED Business Overview
  82. 6.14.3 PROBIOMED Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 PROBIOMED Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  84. 6.14.5 PROBIOMED Recent Developments
  85. 6.15 Momenta Pharmaceuticals
  86. 6.15.1 Momenta Pharmaceuticals Company Information
  87. 6.15.2 Momenta Pharmaceuticals Business Overview
  88. 6.15.3 Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  90. 6.15.5 Momenta Pharmaceuticals Recent Developments
  91. 6.16 MedImmune
  92. 6.16.1 MedImmune Company Information
  93. 6.16.2 MedImmune Business Overview
  94. 6.16.3 MedImmune Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 MedImmune Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  96. 6.16.5 MedImmune Recent Developments
  97. 6.17 LG Life Sciences
  98. 6.17.1 LG Life Sciences Company Information
  99. 6.17.2 LG Life Sciences Business Overview
  100. 6.17.3 LG Life Sciences Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 LG Life Sciences Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  102. 6.17.5 LG Life Sciences Recent Developments
  103. 6.18 LEO Pharma
  104. 6.18.1 LEO Pharma Company Information
  105. 6.18.2 LEO Pharma Business Overview
  106. 6.18.3 LEO Pharma Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  107. 6.18.4 LEO Pharma Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  108. 6.18.5 LEO Pharma Recent Developments
  109. 6.19 Janssen Biotech
  110. 6.19.1 Janssen Biotech Company Information
  111. 6.19.2 Janssen Biotech Business Overview
  112. 6.19.3 Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  113. 6.19.4 Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  114. 6.19.5 Janssen Biotech Recent Developments
  115. 6.20 Intas Pharmaceuticals
  116. 6.20.1 Intas Pharmaceuticals Company Information
  117. 6.20.2 Intas Pharmaceuticals Business Overview
  118. 6.20.3 Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  119. 6.20.4 Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  120. 6.20.5 Intas Pharmaceuticals Recent Developments
  121. 6.21 HanAll Biopharma
  122. 6.21.1 HanAll Biopharma Company Information
  123. 6.21.2 HanAll Biopharma Business Overview
  124. 6.21.3 HanAll Biopharma Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  125. 6.21.4 HanAll Biopharma Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  126. 6.21.5 HanAll Biopharma Recent Developments
  127. 6.22 EPIRUS Biopharmaceuticals
  128. 6.22.1 EPIRUS Biopharmaceuticals Company Information
  129. 6.22.2 EPIRUS Biopharmaceuticals Business Overview
  130. 6.22.3 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  131. 6.22.4 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  132. 6.22.5 EPIRUS Biopharmaceuticals Recent Developments
  133. 6.23 Dexa Medica
  134. 6.23.1 Dexa Medica Company Information
  135. 6.23.2 Dexa Medica Business Overview
  136. 6.23.3 Dexa Medica Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  137. 6.23.4 Dexa Medica Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  138. 6.23.5 Dexa Medica Recent Developments
  139. 6.24 Delenex Therapeutics
  140. 6.24.1 Delenex Therapeutics Company Information
  141. 6.24.2 Delenex Therapeutics Business Overview
  142. 6.24.3 Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  143. 6.24.4 Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  144. 6.24.5 Delenex Therapeutics Recent Developments
  145. 6.25 Celltrion
  146. 6.25.1 Celltrion Company Information
  147. 6.25.2 Celltrion Business Overview
  148. 6.25.3 Celltrion Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  149. 6.25.4 Celltrion Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  150. 6.25.5 Celltrion Recent Developments
  151. 6.26 Celgene Corporation
  152. 6.26.1 Celgene Corporation Company Information
  153. 6.26.2 Celgene Corporation Business Overview
  154. 6.26.3 Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  155. 6.26.4 Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  156. 6.26.5 Celgene Corporation Recent Developments
  157. 6.27 CASI Pharmaceuticals
  158. 6.27.1 CASI Pharmaceuticals Company Information
  159. 6.27.2 CASI Pharmaceuticals Business Overview
  160. 6.27.3 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  161. 6.27.4 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  162. 6.27.5 CASI Pharmaceuticals Recent Developments
  163. 6.28 Bionovis
  164. 6.28.1 Bionovis Company Information
  165. 6.28.2 Bionovis Business Overview
  166. 6.28.3 Bionovis Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  167. 6.28.4 Bionovis Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  168. 6.28.5 Bionovis Recent Developments
  169. 6.29 AryoGen Biopharma
  170. 6.29.1 AryoGen Biopharma Company Information
  171. 6.29.2 AryoGen Biopharma Business Overview
  172. 6.29.3 AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  173. 6.29.4 AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  174. 6.29.5 AryoGen Biopharma Recent Developments
  175. 6.30 Apogenix
  176. 6.30.1 Apogenix Company Information
  177. 6.30.2 Apogenix Business Overview
  178. 6.30.3 Apogenix Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  179. 6.30.4 Apogenix Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  180. 6.30.5 Apogenix Recent Developments
7 North America by Country
  1. 7.1 North America Tumor Necrosis Factor Inhibitors Drug Sales by Country
  2. 7.1.1 North America Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Tumor Necrosis Factor Inhibitors Drug Sales by Country (2021-2026)
  4. 7.1.3 North America Tumor Necrosis Factor Inhibitors Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America Tumor Necrosis Factor Inhibitors Drug Market Size by Country
  6. 7.2.1 North America Tumor Necrosis Factor Inhibitors Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Tumor Necrosis Factor Inhibitors Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America Tumor Necrosis Factor Inhibitors Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Tumor Necrosis Factor Inhibitors Drug Sales by Country
  2. 8.1.1 Europe Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Tumor Necrosis Factor Inhibitors Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe Tumor Necrosis Factor Inhibitors Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Tumor Necrosis Factor Inhibitors Drug Market Size by Country
  6. 8.2.1 Europe Tumor Necrosis Factor Inhibitors Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Tumor Necrosis Factor Inhibitors Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe Tumor Necrosis Factor Inhibitors Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales by Country
  2. 9.1.1 Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Market Size by Country
  6. 9.2.1 Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Tumor Necrosis Factor Inhibitors Drug Sales by Country
  2. 10.1.1 South America Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Tumor Necrosis Factor Inhibitors Drug Sales by Country (2021-2026)
  4. 10.1.3 South America Tumor Necrosis Factor Inhibitors Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America Tumor Necrosis Factor Inhibitors Drug Market Size by Country
  6. 10.2.1 South America Tumor Necrosis Factor Inhibitors Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Tumor Necrosis Factor Inhibitors Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America Tumor Necrosis Factor Inhibitors Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales by Country
  2. 11.1.1 Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Market Size by Country
  6. 11.2.1 Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Tumor Necrosis Factor Inhibitors Drug Value Chain Analysis
  2. 12.1.1 Tumor Necrosis Factor Inhibitors Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Tumor Necrosis Factor Inhibitors Drug Production Mode & Process
  7. 12.2 Tumor Necrosis Factor Inhibitors Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Tumor Necrosis Factor Inhibitors Drug Distributors
  10. 12.2.3 Tumor Necrosis Factor Inhibitors Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst